Inactive/Delisted stock
Unicycive Therapeutics Stock (NASDAQ:UNCY)
Previous Close
$5.94
52W Range
$2.02 - $11.00
50D Avg
$6.39
200D Avg
$5.80
Market Cap
$820.28M
Avg Vol (3M)
$446.87K
Beta
2.00
Div Yield
-
UNCY Company Profile
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.